



Published in final edited form as:

J Am Acad Dermatol. 2012 November ; 67(5): 817.e1–828. doi:10.1016/j.jaad.2012.07.022.

Vitamin D in cutaneous carcinogenesis Part II

Jean Y. Tang, MD, PhD^a, Teresa Fu, MD^a, Christopher Lau, BA^b, Dennis H. Oh, MD, PhD^{c,d}, Daniel D. Bikle, MD, PhD^{c,d,e}, and Maryam M. Asgari, MD, MPH^{b,c}

^aDepartment of Dermatology, Stanford University ^bDivision of Research, Kaiser Permanente Northern California, Oakland ^cDepartment of Dermatology, University of California at San Francisco ^dNorthern California Institute for Research and Education, San Francisco Veterans Affairs Medical Center ^eDepartment of Medicine, University of California at San Francisco, California

Abstract

The role of vitamin D in health maintenance and disease prevention in fields ranging from bone metabolism to cancer is currently under intensive investigation. A number of epidemiologic studies have suggested that vitamin D may have a protective effect on cancer risk and cancer-associated mortality. With regard to skin cancer, epidemiologic and laboratory studies suggest that vitamin D and its metabolites may have a similar risk reducing effect. Potential mechanisms of action include inhibition of the hedgehog signaling pathway and upregulation of nucleotide excision repair enzymes. The key factor complicating the association between vitamin D and skin cancer is ultraviolet B radiation. The same spectrum of ultraviolet B radiation that catalyzes the production of vitamin D in the skin also causes DNA damage that can lead to epidermal malignancies. Part II of this continuing medical education article will summarize the literature on vitamin D and skin cancer to identify evidence-based optimal serum levels of vitamin D and to recommend ways of achieving those levels while minimizing the risk of skin cancer.

Keywords

25(OH)D levels; basal cell carcinoma; melanoma; nonmelanoma skin cancer; vitamin D; vitamin D receptor; squamous cell carcinoma; sunlight

Overall, there is some evidence that vitamin D may play a role in nonmelanoma skin cancer (NMSC) and melanoma prevention, although as of yet there is no direct evidence to show a protective effect. The relative contributions of diet, supplementation, and cutaneous vitamin D synthesis to serum vitamin D levels need additional study. While some in vitro and animal data suggest that vitamin D may have protective effects against skin cancer, additional studies in humans are needed. Several laboratory studies suggest that vitamin D and its metabolites may reduce the risk of skin cancer by inhibiting the hedgehog signaling pathway, the pathway underlying development of basal cell carcinomas (BCCs), and upregulating DNA nucleotide excision repair enzymes. Mice lacking the vitamin D receptor (VDR) develop increased numbers of NMSCs, and the addition of vitamin D decreases the growth of NMSC and melanoma cells in vitro and in mouse models. In humans, epidemiologic studies have reported mixed findings, with some reporting an association

between higher vitamin D levels and increased skin cancer risk, others showing a decreased skin cancer risk, and still others showing no association.

However, because ultraviolet (UV) rays are known to be carcinogenic, and because it is very difficult to discern when small amounts of sun exposure cross the line from potential benefit to harm, the American Academy of Dermatology recommends that an adequate amount of vitamin D should be obtained from a healthy diet that includes foods and beverages that are naturally rich in or fortified with vitamin D and/or vitamin D supplements; it should not be obtained from unprotected exposure to UV radiation. Therefore, given the current evidence, our recommendations are to follow the recent Institute of Medicine (IOM) guidelines: assuming minimal or no sun exposure, most healthy individuals will need 600 IU of vitamin D daily to maintain serum 25(OH)D levels above 20 ng/mL, and higher doses up to 4000 IU daily are safe but not necessarily beneficial.

For clinicians, it may be prudent to test serum 25(OH)D levels once in patients of clinical concern or in those at risk for vitamin D deficiency (ie, individuals with dark skin or who have little outdoor sun exposure, such as the elderly or those that practice rigorous sun protection); appropriate doses of vitamin D supplementation can then be calculated to achieve and maintain serum 25(OH)D levels above 20 ng/mL. According to the Endocrine Society Practice Guidelines, individuals without risk factors for vitamin D deficiency should not be screened. There is no evidence for the benefit of screening for vitamin D deficiency in the general population.

ROLE OF VITAMIN D IN KERATINOCYTES

Key points

- Laboratory and preclinical data suggest a role of vitamin D in the reduction and prevention of keratinocytic carcinomas
- Vitamin D receptor is present in basal cell and squamous cell carcinoma cells

In the skin, ultraviolet B (UVB) radiation catalyzes the conversion of 7-dehydroxycholesterol to previtamin D₃, thereby starting the synthesis of 1,25(OH)₂D, the active compound that influences the growth and development of keratinocytes.¹ At high levels, 1,25(OH)₂D inhibits keratinocyte proliferation in vitro² and interacts with calcium to regulate keratinocyte differentiation.³ Keratinocytes lacking VDR are hyperproliferative and exhibit decreased apoptosis.⁴ Genetically engineered mice lacking the VDR (VDR knockout mice) have reduced alopecia, abnormal hair follicles, and dermal cysts, indicating a role of VDR in keratinocyte differentiation.⁵ In humans, VDR polymorphisms are associated with increased development of solar keratoses⁶ and differing melanoma risk.⁷ Several cofactor proteins that modulate the interaction between VDR and the transcription machinery are differentially associated with the VDR in proliferating versus differentiating keratinocytes and also have a different profile in early and late cellular differentiation.⁸ This allows keratinocytes to fine tune their response to 1,25(OH)₂D.

UVB damages keratinocyte DNA through the formation of mutagenic cyclobutane dimers, and vitamin D may have a protective effect against UV radiation—induced dimer formation. Wong et al⁹ and De Haes et al¹⁰ showed exogenously applied 1,25(OH)₂D blocks the formation of cyclobutane dimers in vitro. Similarly, microarray studies of keratinocytes treated with 1,25(OH)₂D show the upregulated expression of 2 DNA repair genes, XPC and DDB2, suggesting that the protective effect of 1,25(OH)₂D is related to enhancement of the DNA repair process.¹¹ Similar results have been seen in mouse model studies.^{12,13}

The photoprotective effect of 1,25(OH)₂D on keratinocytes may be dose-dependent.^{14–16} In one study, pretreatment of keratinocytes with 1,25(OH)₂D before exposure to UVB radiation at 30 to 40 mJ/cm² decreased photodamage, but this effect was not seen at higher doses of UVB (50 mJ/cm²).¹⁵ These findings suggest that 1,25(OH)₂D exerts its photoprotective effect against a moderate range of UVB irradiation, but that at higher doses, this effect is lost, possibly explaining why chronic, high-dose UVB exposure is associated with increased skin cancer risk.

Role of vitamin D in basal cell carcinoma

Vitamin D has been shown to inhibit the hedgehog signaling pathway, a key tumor pathway driving the development of BCCs.^{17–19} This pathway is normally suppressed by the PATCHED1 (PTCH1) protein, and mutations in *PTCH1* gene lead the rare disease basal cell nevus syndrome.²⁰

Like the keratinocytes from which they are derived, BCCs also express VDR.^{21,22} In one study, peripheral cells in human BCC tumors had a greater expression of VDR than adjacent or unaffected epidermal cells. In an animal model, VDR knockout mice developed more skin tumors (primarily BCCs) when exposed to a carcinogen (oral 7,12-dimethylbenz[a]anthracene) than did their wildtype littermate.²³ The development of BCCs in these mice lacking functional VDR suggests the importance of the vitamin D pathway in regulating genes downstream of the hedgehog signaling pathway. In mice, topical application of vitamin D₃ reduces BCC cell proliferation and downregulates Gli1 mRNA both in vitro and in vivo.²⁴

In humans, clinical studies of BCC patients also show a potential role for vitamin D. In a nested case control study of elderly men with NMSC (N = 178) or without skin cancer (N = 930) enrolled in the Osteoporotic Fractures in Men (MrOS) study, men with the highest baseline serum 25(OH)D levels (>30 ng/mL) had 47% lower odds of NMSC (95% confidence interval, 0.3–0.93; *P* = .026; *P* for trend, 0.04) compared to those with the lowest baseline 25(OH)D levels.²⁵ A diagnosis of NMSC is therefore not a surrogate for adequate 25(OH)D levels, and high 25(OH)D levels may be associated with a reduced risk of NMSC. In contrast, another case control study from the Kaiser population found that higher prediagnostic 25(OH)D levels were associated with a small increased risk of BCC.²⁶ However, an older prospective cohort study on vitamin D intake from dietary questionnaires found no association between vitamin D and BCC risk.²⁷ Eide et al²⁸ found that higher 25(OH)D levels were associated with an increased risk of NMSC in a prospective Health Maintenance Organization cohort of white patients who sought advice on the risk of osteoporosis.²⁸ The positive relationship of UV exposure with both vitamin D synthesis and NMSC may explain their findings, and sunlight exposure is a highly likely confounder. These 3 observational epidemiologic studies are difficult to directly compare because study subjects differed in geographic location/latitudes, and study measurements varied between measuring 1,25(OH)₂D and 25(OH)D levels, accounting for total vitamin D versus using dietary intake journals, and including BCCs versus counting all NMSCs. Taken together, the current laboratory evidence suggests that vitamin D may prevent development of BCCs, but additional prospective studies in humans are needed to better define the true relationship between vitamin D levels and BCC risk.

Role of vitamin D in squamous cell carcinoma

Mice lacking VDR are predisposed to SCC formation when exposed to high and prolonged doses of UVB.⁴ In addition, as in BCCs, 1,25(OH)₂D has been shown to inhibit the growth of SCCs both in vivo and in vitro. Vitamin D analogs inhibit cell growth by inducing cell cycle arrest, inhibiting DNA synthesis, and inducing apoptosis in SCC cell lines.²⁹ In mice,

topically applied 1,25(OH)₂D inhibits chemically induced tumor formation in a dose-dependent manner^{30–32}; similar results have been shown with vitamin D analogs.³³ In addition, the topical application of 1,25(OH)₂D appears to accelerate the clearance of cyclobutane dimers that are characteristic of UV radiation—induced DNA damage.⁹ The underlying molecular mechanism has not been fully elucidated, but molecular studies show that the VDR is induced by an isoform of the tumor suppressor gene p63, a gene that, along with p53, is critical for keratinocytes' ability to initiate the DNA repair process after UV exposure.³⁴ Therefore, vitamin D may interact with tumor suppressor genes (p53 or p63) to upregulate nucleotide excision repair genes or other DNA repair enzymes, such as XPC and DDB2.¹¹ This response may differ between normal keratinocytes and SCCs.³⁵

To date, there are limited epidemiologic studies on the effect of vitamin D or its metabolites on SCC prevention or treatment in humans. Eide et al²⁸ showed a serum 25(OH)D level of 15 ng/mL or higher was associated, but not statistically significantly, with increased SCC risk. Despite a growing body of epidemiologic evidence to suggest an association between vitamin D and cancer risk in various visceral organs, data to assess this association in SCCs are lacking. Studies of the epidemiology of BCCs and SCCs are difficult in general to perform because most national registries, such as the Surveillance, Epidemiology, and End Results program, exclude them, leaving no easily accessible database with which to track the development of these cancers. Therefore, although the animal studies are suggestive, additional work is needed to assess the suitability of topical or oral vitamin D₃ for chemoprevention of both BCCs and SCCs in humans.

ROLE OF VITAMIN D IN MELANOCYTES

Key point

- Several studies have reported an association between serum vitamin D levels or intake and melanoma onset and progression

Like keratinocytes, melanocytes also have the capacity for autonomous local production of 1,25(OH)₂D and harbor VDR.³⁶ Such locally produced 1,25(OH)₂D may play a role in innate and acquired cutaneous immunity.³⁷ In vitro, 1,25(OH)₂D stimulates melanocyte maturation, possibly through the stimulation of tyrosinase activity.^{38,39} It also protects cells from apoptosis⁴⁰ and upregulates VDR expression.⁴¹ This has led some researchers to suggest treating vitiligo with vitamin D or a vitamin D analog.^{42,43} However, a recent randomized, doubleblinded trial evaluating the efficacy of topical tacalcitol, a synthetic vitamin D₃ analogue, in adult nonsegmental vitiligo did not show any advantage as compared to sunlight exposure alone.⁴⁴ Nevertheless, there is at least experimental evidence to suggest that the vitamin D pathway plays an important role in melanocyte function and therefore may be involved in melanoma.

Role of vitamin D in melanoma

There is accumulating evidence that the vitamin D pathway may play a role in melanoma. VDR expression has been detected in cultured melanoma cells,^{41,45} melanoma xenografts,⁴⁶ and in primary melanoma tissue.⁴⁷ As with BCCs, VDR expression is stronger in melanoma cell lines than in normal melanocytes.⁴¹ A recent large, international, multicenter, population-based, case control study has identified polymorphisms in the promoter, coding, and 3' gene region of VDR that are significantly associated with melanoma after adjusting for relevant covariates.⁴⁸

The antiproliferative and prodifferentiative effects of vitamin D and its metabolites have been shown in some, but not all, melanoma cell lines.^{36,46,49,50} 1,25(OH)₂D has been shown to inhibit tumor invasion and angiogenesis in melanoma cell lines⁵¹ and to suppress the

growth of human-derived melanoma xenografts in immunosuppressed mice.⁵² An inhibitory effect of vitamin D on melanoma migration, invasion, and metastasis has been shown in mice that have been inoculated with vitamin D—treated melanoma cells.⁵³ Finally, Albert et al⁵⁴ reported that vitamin D analogs inhibit the growth of pigmented ocular tumors in transgenic mice.

In humans, several studies have reported an association between serum vitamin D levels or intake and melanoma onset and progression, although others have failed to find any association. Studies on VDR polymorphisms and melanoma risk are also emerging. A summary of all published studies on the relationship between vitamin D serum levels or intake and melanoma risk is shown in Table I. In a prospective study by Newton-Bishop et al,⁵⁵ patients with high serum 25(OH)D levels at the time of melanoma diagnosis had thinner tumors, a lower risk of relapse, and a higher overall survival rate compared to those with low serum 25(OH)D levels. In this cohort, there was also evidence of interaction between the VDR BsmI genotype and serum 25(OH) D levels on relapse-free survival. In another case control study by Nurnberg et al,⁵⁶ 25(OH)D levels were significantly reduced in patients with stage IV melanoma patients compared to stage I patients, and patients with serum levels <10 ng/mL tended to have earlier distant metastases compared to patients with serum levels >20 ng/mL. Because serum 25(OH)D at presentation is likely to be a reflection of levels before and during early development of the melanoma, it would seem that vitamin D may inhibit local invasion and micrometastases during early tumor development. However, other studies have found no relationship between 25(OH)D levels and melanoma,⁵⁷ so the exact relationship between vitamin D and melanoma is yet to be elucidated.

Regarding the dietary intake of vitamin D, a large case control study of dietary and supplemental intake of vitamin D in melanoma found that high vitamin D intake from food was associated with a reduction in melanoma risk, although after accounting for vitamin D from supplements, the association between intake of vitamin D and risk for melanoma was no longer statistically significant.⁵⁸ Another dataset using a large prospective cohort found no association between dietary and supplemental vitamin D intake and melanoma risk among 68,611 men and women participating in the Vitamins and Lifestyle cohort study.⁵⁹ Interestingly, a large prospective study in Norway found an increased risk of melanoma in women who consumed significant amounts of cod liver oil, which contains about 400 to 1000 IU of vitamin D per teaspoon.⁶⁰ However, the cod liver oil effect may not be attributable to a vitamin D—specific effect, because it has other relatively unique nutritional characteristics, including a high concentration of vitamin A and n-3 fatty acids. Finally, a recent post hoc analysis of the Women’s Health Initiative clinical trial (N = 36,282) found no effect of 1000 mg of calcium plus 400 IU of vitamin D supplementation on NMSC and melanoma risk. However, calcium plus vitamin D did reduce melanoma risk by 50% in a subgroup of women with a history of NMSC.⁶¹

At present, there is no current consensus on clinical recommendations for vitamin D intake and optimal serum levels in melanoma patients and those at risk for melanoma. However, laboratory evidence points to a role for vitamin D in melanoma development and tumor progression. A recent review by Field and Newton-Bishop⁶² on melanoma and vitamin D suggests aiming for a target serum level of 70 to 100 nmol/L (28–40 ng/mL) for melanoma patients, because laboratory evidence has shown that maintaining higher serum vitamin D levels may influence tumor cell proliferation. There is currently insufficient evidence to recommend higher doses of vitamin D, and more work is needed to determine how vitamin D may play a protective role against melanoma in humans.

DEFINING OPTIMAL VITAMIN D LEVELS AND RECOMMENDATIONS FOR SUPPLEMENTATION

Key points

- The Institute of Medicine recommends that most healthy individuals will need 600 IU of vitamin D daily to maintain serum 25(OH)D levels above 20 ng/mL
- Higher doses up to 4000 IU daily are safe but not necessarily beneficial
- Symptoms of vitamin D toxicity are nonspecific and include nausea, vomiting, poor appetite, constipation, weakness, and weight loss

Serum concentration of 25(OH)D is the best indicator of vitamin D status given its long half-life of over 250 hours. It does not reflect total tissue stores, but shows the amount of available precursor to the active form, 1,25(OH)₂D. Because of its short half-life and tight regulation, circulating levels of 1,25(OH)₂D are generally not a good indicator of vitamin D status; levels do not typically decrease until vitamin D deficiency is severe (with the exception of sarcoidosis).⁶³ The optimal serum vitamin D levels for health maintenance and disease prevention are still under debate, but the recent 2010 IOM recommendations state that vitamin D deficiency is defined as levels <20 ng/mL (<50 nmol/L); levels below this threshold are generally considered inadequate for maintaining bone health⁶⁴ (Table II). Some have argued that the role of vitamin D in other aspects of health necessitate higher 25(OH)D serum levels between 28 and 40 ng/mL,⁶⁵ but the IOM has concluded that compelling evidence for this recommendation does not yet exist.

Vitamin D toxicity

The IOM report addresses concerns that some people will oversupplement with vitamin D, leading to adverse side effects. Excessive sun exposure does not result in vitamin D toxicity, because with sustained exposure vitamin D₃ begins to degrade as it is formed.⁶⁶ Given that vitamin D is difficult to obtain from natural dietary sources, toxicity is unlikely to result from dietary intake unless large amounts of cod liver oil are consumed. It is more likely to occur from the excessive intake of supplements. Long-term intakes above the recommended maximum dose, or 4000 IU (Table III), can increase the risk of adverse health effects. However, short-term or periodic bursts with large doses (eg, 50,000 IU/week for 8 weeks) have been used clinically and do not appear to cause toxicity.⁶⁷ The excess supply is stored and used as needed to maintain normal serum 25(OH)D concentrations when vitamin D intake or sun exposure is limited. With regard to excessively high serum levels, although serum 25(OH)D concentrations 400 ng/mL (1000 nmol/L) were not associated with harm in animal models,⁶⁸ in humans a serum 25(OH)D concentration that is consistently >200 ng/mL (>500 nmol/L) is considered to be potentially toxic.⁶⁹ Symptoms of vitamin D toxicity are nonspecific and include nausea, vomiting, poor appetite, constipation, weakness, and weight loss.^{70,71} If the excess vitamin D leads to severe hypercalcemia, more serious side effects can arise, such as mental status changes, confusion, and cardiac arrhythmia. In fact, a study of 10 National Cancer Institute cohorts (with almost 2 million subjects), chronic 25(OH)D levels >40 ng/mL (100 nmol/L) were associated with an increased risk for pancreatic cancer.⁷²

Although the effects of vitamin D supplements alone on kidney stone risk have not been evaluated, it is worth noting that in the Women's Health Initiative calcium and vitamin D trial, the use of supplements containing 1000 mg per day of calcium and 400 IU per day of vitamin D led to a 17% increase in the risk of kidney stones over 7 years⁷³ in postmenopausal women.

The current upper limits for vitamin D are listed in Table III and range from 1000 to 4000 IU daily, depending on age.⁶⁴ Some studies show that prolonged daily intake of 10,000 IU (250 µg) poses little risk.^{74,75} However, given the small but real risks posed by even low doses, such as the 400 IU of vitamin D tested in the Women's Health Initiative trials, we recommend that most people should not exceed the 4000 IU daily limit set by the IOM.

Supplementation

The intake of 1 µg (40 IU) of vitamin D per day increases serum 25(OH)D by an average of 0.4 ng/mL.^{76,77} The recent IOM report on vitamin D states that 600 IU daily is enough to meet the needs of most North Americans.⁶⁴ For an individual with serum 25(OH)D levels <20 ng/mL, a daily dose of 600 IU would raise levels by about 6 ng/mL. Some organizations, including the Canadian Cancer Society, recommended that adults consider taking 1000 IU of vitamin D per day during the fall and winter⁷⁸ or if they are using photoprotection on a regular basis. The American Academy of Dermatology recently updated its recommendations on vitamin D to state that there is no known safe level of UV exposure, that regular photoprotection reduces risk for skin cancer, and to recommend that people follow the updated IOM recommendations for daily intake levels.⁷⁹

For clinicians, it may be prudent to test serum 25(OH)D levels once in patients of clinical concern or in those at risk for vitamin D deficiency (ie, individuals with dark skin or individuals who have little outdoor sun exposure, such as the elderly or those that practice rigorous sun protection); appropriate doses of vitamin D supplementation can then be calculated to achieve and maintain serum 25(OH)D levels above 20 ng/mL. The Endocrine Society Practice Guidelines recommends that all adults who are vitamin D—deficient be treated with 50,000 IU of vitamin D₂ or vitamin D₃ once a week for 8 weeks or its equivalent of 6000 IU per day of vitamin D₂ or vitamin D₃.⁸⁰ After 8 weeks, serum 25(OH)D levels should be rechecked and patients who do not have their vitamin D deficiency corrected should be referred to their primary care physician or endocrinologist for further management.

Overall, there is some evidence that vitamin D may play a role in NMSC and melanoma prevention, although as of yet there is no direct evidence to show a protective effect. The relative contributions of diet, supplementation, and cutaneous vitamin D synthesis to serum vitamin D levels require additional study. While some in vitro data suggest that vitamin D associated with low levels of UV exposure may have protective effects against skin cancer, additional studies in humans are needed. However, because UV rays are known to be carcinogenic, and because it is difficult to discern when small amounts of sun exposure cross the line from potential benefit to harm, one can argue that it is prudent to advise sun protection and to recommend obtaining vitamin D from supplemental sources that do not have a narrow therapeutic index.

The American Academy of Dermatology recommends that an adequate amount of vitamin D should be obtained from a healthy diet that includes foods and beverages that are naturally rich in or fortified with vitamin D and/or vitamin D supplements; it should not be obtained from unprotected exposure to UV radiation. Given the current evidence, our current recommendations are to follow the recent IOM guidelines: assuming minimal sun exposure, most healthy individuals will need 600 IU of vitamin D daily to maintain serum 25(OH)D levels above 20 ng/mL, and higher doses up to 4000 IU daily are safe but not necessarily beneficial. Those who regularly practice photoprotective behaviors may especially benefit from supplementation. Additional research is needed to better define the relationship between vitamin D intake, serum 25(OH)D levels, and the risk of NMSC and melanoma.

Acknowledgments

The authors thank Olena Mykhaylichenko for manuscript preparation.

Supported by National Institute of Arthritis and Musculoskeletal and Skin Diseases grants K23 AR 051037-01 (Dr Asgari) and K23 AR 056736-01 (Dr Tang), the Damon Runyon Clinical Investigator Award (Dr Tang), and the VA Office of Research and Development Merit Award I01BX007080 (Dr Oh).

Abbreviations used

1,25(OH)₂D	1,25-dihydroxyvitamin D ₃ , the biologically active form of serum vitamin D
25(OH)D	25-hydroxyvitamin D
IOM	Institute of Medicine
IU	International Unit
NMSC	nonmelanoma skin cancer
UV	ultraviolet
UVB	ultraviolet B
VDR	vitamin D receptor

REFERENCES

- Hosomi J, Hosoi J, Abe E, Suda T, Kuroki T. Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha,25-dihydroxyvitamin D₃. *Endocrinology*. 1983; 113:1950–1957. [PubMed: 6196178]
- Popadic S, Ramic Z, Medenica L, Mostarica Stojkovic M, Trajkovic V, Popadic D. Antiproliferative effect of vitamin A and D analogues on adult human keratinocytes in vitro. *Skin Pharmacol Physiol*. 2008; 21:227–234. [PubMed: 18509257]
- Bikle DD, Gee E, Pillai S. Regulation of keratinocyte growth, differentiation, and vitamin D metabolism by analogs of 1,25-dihydroxyvitamin D. *J Invest Dermatol*. 1993; 101:713–718. [PubMed: 8228333]
- Ellison TI, Smith MK, Gilliam AC, MacDonald PN. Inactivation of the vitamin D receptor enhances susceptibility of murine skin to UV-induced tumorigenesis. *J Invest Dermatol*. 2008; 128:2508–2517. [PubMed: 18509362]
- Bikle DD, Chang S, Crumrine D, Elalieh H, Man MQ, Dardenne O, et al. Mice lacking 25OHD 1alpha-hydroxylase demonstrate decreased epidermal differentiation and barrier function. *J Steroid Biochem Mol Biol*. 2004; 89–90:347–353.
- Carless MA, Kraska T, Lintell N, Neale RE, Green AC, Griffiths LR. Polymorphisms of the VDR gene are associated with presence of solar keratoses on the skin. *Br J Dermatol*. 2008; 159:804–810. [PubMed: 18647306]
- Mocellin S, Nitti D. Vitamin D receptor polymorphisms and the risk of cutaneous melanoma: a systematic review and meta-analysis. *Cancer*. 2008; 113:2398–2407. [PubMed: 18816636]
- Hawker NP, Pennypacker SD, Chang SM, Bikle DD. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. *J Invest Dermatol*. 2007; 127:874–880. [PubMed: 17082781]
- Wong G, Gupta R, Dixon KM, Deo SS, Choong SM, Halliday GM, et al. 1,25-Dihydroxyvitamin D and three low-calcemic analogs decrease UV-induced DNA damage via the rapid response pathway. *J Steroid Biochem Mol Biol*. 2004; 89–90:567–570.
- De Haes P, Garmyn M, Verstuyf A, De Clercq P, Vandewalle M, Degreef H, et al. 1,25-Dihydroxyvitamin D₃ and analogues protect primary human keratinocytes against UVB-induced DNA damage. *J Photochem Photobiol B*. 2005; 78:141–148. [PubMed: 15664501]

11. Moll PR, Sander V, Frischauf AM, Richter K. Expression profiling of vitamin D treated primary human keratinocytes. *J Cell Biochem.* 2007; 100:574–592. [PubMed: 16960875]
12. Dixon KM, Deo SS, Wong G, Slater M, Norman AW, Bishop JE, et al. Skin cancer prevention: a possible role of 1,25dihydroxy-vitamin D3 and its analogs. *J Steroid Biochem Mol Biol.* 2005; 97:137–143. [PubMed: 16039116]
13. Gupta R, Dixon KM, Deo SS, Holliday CJ, Slater M, Halliday GM, et al. Photoprotection by 1,25 dihydroxyvitamin D3 is associated with an increase in p53 and a decrease in nitric oxide products. *J Invest Dermatol.* 2007; 127:707–715. [PubMed: 17170736]
14. Hanada K, Sawamura D, Nakano H, Hashimoto I. Possible role of 1,25-dihydroxyvitamin D3-induced metallothionein in photoprotection against UVB injury in mouse skin and cultured rat keratinocytes. *J Dermatol Sci.* 1995; 9:203–208. [PubMed: 8664218]
15. Lee J, Youn JI. The photoprotective effect of 1,25-dihydroxyvitamin D3 on ultraviolet light B-induced damage in keratinocyte and its mechanism of action. *J Dermatol Sci.* 1998; 18:11–18. [PubMed: 9747657]
16. De Haes P, Garmyn M, Degreef H, Vantieghem K, Bouillon R, Segaeert S. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. *J Cell Biochem.* 2003; 89:663–673. [PubMed: 12858333]
17. Bijlsma MF, Spek CA, Zivkovic D, van de Water S, Rezaee F, Peppelenbosch MP. Repression of smoothed by patched-dependent (pro-)vitamin D3 secretion. *PLoS Biol.* 2006; 4:e232. [PubMed: 16895439]
18. Tang JY, So PL, Epstein EH Jr. Novel Hedgehog pathway targets against basal cell carcinoma. *Toxicol Appl Pharmacol.* 2007; 224:257–264. [PubMed: 17276471]
19. Aszterbaum M, Rothman A, Johnson RL, Fisher M, Xie J, Bonifas JM, et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. *J Invest Dermatol.* 1998; 110:885–888. [PubMed: 9620294]
20. Epstein EH. Basal cell carcinomas: attack of the hedgehog. *Nat Rev Cancer.* 2008; 8:743–754. [PubMed: 18813320]
21. Kamradt J, Rafi L, Mitschele T, Meineke V, Gartner BC, Wolfgang T, et al. Analysis of the vitamin D system in cutaneous malignancies. *Recent Results Cancer Res.* 2003; 164:259–269. [PubMed: 12899528]
22. Mitschele T, Diesel B, Friedrich M, Meineke V, Maas RM, Gartner BC, et al. Analysis of the vitamin D system in basal cell carcinomas (BCCs). *Lab Invest.* 2004; 84:693–702. [PubMed: 15077124]
23. Zinser GM, Suckow M, Welsh J. Vitamin D receptor (VDR) ablation alters carcinogen-induced tumorigenesis in mammary gland, epidermis and lymphoid tissues. *J Steroid Biochem Mol Biol.* 2005; 97:153–164. [PubMed: 16111884]
24. Tang JY, Xiao TZ, Oda Y, Chang KS, Shpall E, Wu A, et al. Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas. *Cancer Prev Res (Phil).* 2011; 4:744–751.
25. Tang JY, Parimi N, Wu A, Boscardin WJ, Shikany JM, Chren MM, et al. Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men. *Cancer Causes Control.* 2010; 21:387–391. [PubMed: 19921445]
26. Asgari MM, Tang J, Warton ME, Chren MM, Quesenberry CP Jr, Bikle D, et al. Association of prediagnostic serum vitamin D levels with the development of basal cell carcinoma. *J Invest Dermatol.* 2010; 130:1438–1443. [PubMed: 20043012]
27. Hunter DJ, Colditz GA, Stampfer MJ, Rosner B, Willett WC, Speizer FE. Diet and risk of basal cell carcinoma of the skin in a prospective cohort of women. *Ann Epidemiol.* 1992; 2:231–239. [PubMed: 1342273]
28. Eide MJ, Johnson DA, Jacobsen GR, Krajenta RJ, Rao DS, Lim HW, et al. Vitamin D and nonmelanoma skin cancer in a health maintenance organization cohort. *Arch Dermatol.* 2011; 147:1379–1384. [PubMed: 21844426]
29. Alagbala AA, Johnson CS, Trump DL, Posner GH, Foster BA. Antitumor effects of two less-calcemic vitamin D analogs (Paricalcitol and QW-1624F2-2) in squamous cell carcinoma cells. *Oncology.* 2006; 70:483–492. [PubMed: 17237623]

30. Hershberger PA, Modzelewski RA, Shurin ZR, Rueger RM, Trump DL, Johnson CS. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. *Cancer Res.* 1999; 59:2644–2649. [PubMed: 10363987]
31. Wood AW, Chang RL, Huang MT, Uskokovic M, Conney AH. 1 alpha, 25-Dihydroxyvitamin D3 inhibits phorbol ester-dependent chemical carcinogenesis in mouse skin. *Biochem Biophys Res Commun.* 1983; 116:605–611. [PubMed: 6689123]
32. Chida K, Hashiba H, Fukushima M, Suda T, Kuroki T. Inhibition of tumor promotion in mouse skin by 1 alpha,25-dihydroxyvitamin D3. *Cancer Res.* 1985; 45:5426–5430. [PubMed: 3840412]
33. Kensler TW, Dolan PM, Gange SJ, Lee JK, Wang Q, Posner GH. Conceptually new deltanoids (vitamin D analogs) inhibit multistage skin tumorigenesis. *Carcinogenesis.* 2000; 21:1341–1345. [PubMed: 10874012]
34. Ferguson-Yates BE, Li H, Dong TK, Hsiao JL, Oh DH. Impaired repair of cyclobutane pyrimidine dimers in human keratinocytes deficient in p53 and p63. *Carcinogenesis.* 2008; 29:70–75. [PubMed: 17984111]
35. Quigley DA, To MD, Perez-Losada J, Pelorosso FG, Mao JH, Nagase H, et al. Genetic architecture of mouse skin inflammation and tumour susceptibility. *Nature.* 2009; 458:505–508. [PubMed: 19136944]
36. Seifert M, Rech M, Meineke V, Tilgen W, Reichrath J. Differential biological effects of 1,25-dihydroxyvitamin D3 on melanoma cell lines in vitro. *J Steroid Biochem Mol Biol.* 2004; 89–90:375–379.
37. Egan KM. Vitamin D and melanoma. *Ann Epidemiol.* 2009; 19:455–461. [PubMed: 19282200]
38. Watabe H, Soma Y, Kawa Y, Ito M, Ooka S, Ohsumi K, et al. Differentiation of murine melanocyte precursors induced by 1,25-dihydroxyvitamin D3 is associated with the stimulation of endothelin B receptor expression. *J Invest Dermatol.* 2002; 119:583–589. [PubMed: 12230499]
39. Ranson M, Posen S, Mason RS. Human melanocytes as a target tissue for hormones: in vitro studies with 1 alpha-25, dihydroxyvitamin D3, alpha-melanocyte stimulating hormone, and beta-estradiol. *J Invest Dermatol.* 1988; 91:593–598. [PubMed: 2848074]
40. Sauer B, Ruwisch L, Kleuser B. Antiapoptotic action of 1alpha,25-dihydroxyvitamin D3 in primary human melanocytes. *Melanoma Res.* 2003; 13:339–347. [PubMed: 12883359]
41. Sertznig P, Seifert M, Tilgen W, Reichrath J. Activation of vitamin D receptor (VDR)- and peroxisome proliferator-activated receptor (PPAR)-signaling pathways through 1,25(OH)(2)D(3) in melanoma cell lines and other skin-derived cell lines. *Dermatoendocrinol.* 2009; 1:232–238. [PubMed: 20592797]
42. Birlea SA, Costin GE, Norris DA. New insights on therapy with vitamin D analogs targeting the intracellular pathways that control repigmentation in human vitiligo. *Med Res Rev.* 2009; 29:514–546. [PubMed: 19241402]
43. Mahmoud BH, Hexsel CL, Hamzavi IH. An update on new and emerging options for the treatment of vitiligo. *Skin Ther Lett.* 2008; 13:1–6.
44. Rodriguez-Martin M, Garcia Bustinduy M, Saez Rodriguez M, Noda Cabrera A. Randomized, double-blind clinical trial to evaluate the efficacy of topical tacalcitol and sunlight exposure in the treatment of adult nonsegmental vitiligo. *Br J Dermatol.* 2009; 160:409–414. [PubMed: 19016706]
45. Colston K, Colston MJ, Fieldsteel AH, Feldman D. 1,25-dihydroxyvitamin D3 receptors in human epithelial cancer cell lines. *Cancer Res.* 1982; 42:856–859. [PubMed: 6895862]
46. Colston K, Colston MJ, Feldman D. 1,25-dihydroxyvitaminD3and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. *Endocrinology.* 1981; 108:1083–1086. [PubMed: 6257495]
47. Reichrath J, Rafi L, Rech M, Meineke V, Tilgen W, Seifert M. No evidence for amplification of 25-hydroxyvitamin D-1alpha-O-Hase (1alpha-OHase) or 1,25-dihydroxyvitamin D-24-OHase (24-OHase) genes in malignant melanoma (MM). *J Steroid Biochem Mol Biol.* 2004; 89–90:163–166.
48. Orlow I, Roy P, Reiner AS, Yoo S, Patel H, Paine S, et al. Vitamin D receptor polymorphisms in patients with cutaneous melanoma. *Int J Cancer.* 2012; 130:405–418. [PubMed: 21365644]

49. Evans SR, Houghton AM, Schumaker L, Brenner RV, Buras RR, Davoodi F, et al. Vitamin D receptor and growth inhibition by 1,25-dihydroxyvitamin D3 in human malignant melanoma cell lines. *J Surg Res.* 1996; 61:127–133. [PubMed: 8769954]
50. Reichrath J, Rech M, Moeini M, Meese E, Tilgen W, Seifert M. In vitro comparison of the vitamin D endocrine system in 1,25(OH)2D3-responsive and -resistant melanoma cells. *Cancer Biol Ther.* 2007; 6:48–55. [PubMed: 17172823]
51. Osborne JE, Hutchinson PE. Vitamin D and systemic cancer: is this relevant to malignant melanoma? *Br J Dermatol.* 2002; 147:197–213. [PubMed: 12174089]
52. Eisman JA, Barkla DH, Tutton PJ. Suppression of in vivo growth of human cancer solid tumor xenografts by 1,25-dihydroxyvitamin D3. *Cancer Res.* 1987; 47:21–25. [PubMed: 3024816]
53. Yudoh K, Matsuno H, Kimura T. 1alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. *J Lab Clin Med.* 1999; 133:120–128. [PubMed: 9989763]
54. Albert DM, Kumar A, Strugnell SA, Darjatmoko SR, Lokken JM, Lindstrom MJ, et al. Effectiveness of 1alpha-hydroxyvitamin D2 in inhibiting tumor growth in a murine transgenic pigmented ocular tumor model. *Arch Ophthalmol.* 2004; 122:1365–1369. [PubMed: 15364717]
55. Newton-Bishop JA, Beswick S, Randerson-Moor J, Chang YM, Affleck P, Elliott F, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. *J Clin Oncol.* 2009; 27:5439–5444. [PubMed: 19770375]
56. Nurnberg B, Graber S, Gartner B, Geisel J, Pfohler C, Schadendorf D, et al. Reduced serum 25-hydroxyvitamin D levels in stage IV melanoma patients. *Anticancer Res.* 2009; 29:3669–3674. [PubMed: 19667163]
57. Randerson-Moor JA, Taylor JC, Elliott F, Chang YM, Beswick S, Kukalich K, et al. Vitamin D receptor gene polymorphisms, serum 25-hydroxyvitamin D levels, and melanoma: UK case-control comparisons and a meta-analysis of published VDR data. *Eur J Cancer.* 2009; 45:3271–3281. [PubMed: 19615888]
58. Millen AE, Tucker MA, Hartge P, Halpern A, Elder DE, Dt Guerry, et al. Diet and melanoma in a case-control study. *Cancer Epidemiol Biomarkers Prev.* 2004; 13:1042–1051. [PubMed: 15184262]
59. Asgari MM, Maruti SS, Kushi LH, White E. A cohort study of vitamin D intake and melanoma risk. *J Invest Dermatol.* 2009; 129:1675–1680. [PubMed: 19194478]
60. Veierod MB, Thelle DS, Laake P. Diet and risk of cutaneous malignant melanoma: a prospective study of 50,757 Norwegian men and women. *Int J Cancer.* 1997; 71:600–604. [PubMed: 9178814]
61. Tang JY, Fu T, Leblanc E, Manson JE, Feldman D, Linos E, et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial. *J Clin Oncol.* 2011; 29:3078–3084. [PubMed: 21709199]
62. Field S, Newton-Bishop JA. Melanoma and vitamin D. *Mol Oncol.* 2011; 5:197–214. [PubMed: 21371954]
63. Sage RJ, Rao DS, Burke RR, Lim HW. Preventing vitamin D toxicity in patients with sarcoidosis. *J Am Acad Dermatol.* 2011; 64:795–796. [PubMed: 21414506]
64. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. *J Clin Endocrinol Metab.* 2011; 96:53–58. [PubMed: 21118827]
65. Vieth R. Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults. *J Steroid Biochem Mol Biol.* 2004; 89–90:575–579.
66. Matsuoka LY, Wortsman J, Haddad JG, Hollis BW. In vivo threshold for cutaneous synthesis of vitamin D3. *J Lab Clin Med.* 1989; 114:301–305. [PubMed: 2549141]
67. Binkley N, Gemar D, Engelke J, Gangnon R, Ramamurthy R, Krueger D, et al. Evaluation of ergocalciferol or cholecalciferol dosing, 1,600 IU daily or 50,000 IU monthly in older adults. *J Clin Endocrinol Metab.* 2011; 96:981–988. [PubMed: 21289249]
68. Shepard RM, DeLuca HF. Determination of vitamin D and its metabolites in plasma. *Methods Enzymol.* 1980; 67:393–413. [PubMed: 6245331]

69. Jones G. Pharmacokinetics of vitamin D toxicity. *Am J Clin Nutr.* 2008; 88:582S–586S. [PubMed: 18689406]
70. Vieth, R. Vitamin D. toxicity, policy, and science. *J Bone Miner Res.* 2007; 22(suppl 2):V64–V68. [PubMed: 18290725]
71. Chesney RW. Vitamin D: can an upper limit be defined? *J Nutr.* 1989; 119:1825–1828. [PubMed: 2693642]
72. Helzlsouer KJ. Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. *Am J Epidemiol.* 2010; 172:4–9. [PubMed: 20562193]
73. Wactawski-Wende J, Kotchen JM, Anderson GL, Assaf AR, Brunner RL, O’Sullivan MJ, et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. *N Engl J Med.* 2006; 354:684–696. [PubMed: 16481636]
74. Munro I. Derivation of tolerable upper intake levels of nutrients. *Am J Clin Nutr.* 2001; 74:865–867. [PubMed: 11722973]
75. Hathcock JN, Shao A, Vieth R, Heaney R. Risk assessment for vitamin D. *Am J Clin Nutr.* 2007; 85:6–18. [PubMed: 17209171]
76. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. *Am J Clin Nutr.* 2003; 77:204–210. [PubMed: 12499343]
77. Vieth R, Chan PC, MacFarlane GD. Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. *Am J Clin Nutr.* 2001; 73:288–294. [PubMed: 11157326]
78. Canadian Cancer Society web site. [Accessed August 5 2012] Canadian Cancer Society announces vitamin D recommendation. Available at: http://www.cancer.ca/Canada-wide/About%20us/Media%20centre/CW-Media%20releases/CW-2007/Canadian%20Cancer%20Society%20Announces%20Vitamin%20D%20Recommendation.aspx?sc_lang=en.
79. American Academy of Dermatology web site. [Accessed August 5 2012] Position statement on vitamin D. Available at: <http://www.aad.org/Forms/Policies/Uploads/PS/PS-Vitamin%20D%20Position%20Statement.pdf>.
80. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab.* 2011; 96:1911–1930. [PubMed: 21646368]
81. Cornwell ML, Comstock GW, Holick MF, Bush TL. Prediagnostic serum levels of 1,25-dihydroxyvitamin D and malignant melanoma. *Photodermatol Photoimmunol Photomed.* 1992; 9:109–112. [PubMed: 1300138]
82. Weinstock MA, Stampfer MJ, Lew RA, Willett WC, Sober AJ. Case-control study of melanoma and dietary vitamin D: implications for advocacy of sun protection and sunscreen use. *J Invest Dermatol.* 1992; 98:809–811. [PubMed: 1569330]
83. Vinceti M, Malagoli C, Fiorentini C, Longo C, Crespi CM, Albertini G, et al. (2011) Inverse association between dietary vitamin D and risk of cutaneous melanoma in a northern Italy population. *Nutr Cancer.* 2011; 63:506–513. [PubMed: 21541899]

CAPSULE SUMMARY

- Vitamin D deficiency is defined as serum 25(OH)D levels below 20 ng/mL.
- Vitamin D in vitro inhibits keratinocyte growth and promotes differentiation—factors that are important for skin cancer prevention.
- Mice lacking the vitamin D receptor have increased basal cell and squamous cell carcinoma tumors, suggesting a role of vitamin D in keratinocytic carcinoma.
- However, epidemiologic studies do not show a clear relationship between vitamin D levels and the risk of nonmelanoma skin cancer.
- Some, but not all, epidemiologic studies show that higher levels of vitamin D are correlated with reduced melanoma risk and improved survival.
- There is no current consensus on clinical recommendations for vitamin D intake and optimal vitamin D levels for skin cancer prevention.

Table 1

Description of studies examining melanoma risk and Vitamin D status

Study design	Country	Risk measure	No. of cases	OR or RR (95% CI)	Protective effect	Covariates	Reference
Serum 25(OH)D levels							
Case control	USA	Melanoma risk	23	1.6 (0.5–6.1)	None	Age, sex, smoking, month of sampling, education, and supplement use	Comwell et al, ⁸¹ 1992
Case control	England	Melanoma risk	941	0.94 (0.79–1.12)	None	Age, sex, month of sampling, and BMI	Randerson-Moor et al, ⁵⁷ 2009
Prospective cohort	England	Melanoma relapse	872	0.79 (0.64–0.96)	Yes [†]	Age, sex, tumor site, BMI, Breslow thickness, and Townsend score	Newton-Bishop et al, ⁵⁵ 2010
		Overall survival	872	0.83 (0.68–1.02)	None		
Case control	Germany	Stage IV vs I patients	205	13.1 ng/mL vs 16.4 ng/mL ($P = .006^*$)	Yes [†]	Age, gender, BMI, historical sun exposure, skin type, number of painful sunburns, and sunscreen use	Nurnberg et al, ⁵⁶ 2009 [*]
Vitamin D intake							
Case control	USA	Melanoma risk	165	1.80 (0.90–3.50)	None	Age, hair color, and family history	Weinstock et al, ⁸² 1992
Case control	USA	Melanoma risk	502	0.61 (0.40–0.95)	Yes [†]	Age, sex, dysplastic nevi, education, and skin type	Millen et al, ⁵⁸ 2004
Case control	Italy	Melanoma risk	380	0.85 (0.74–0.97)	Yes	Age, gender, skin type, history of sun exposure, sunburns, use of sunscreen, and total energy intake	Vinceti et al ⁸³
Prospective cohort	USA	Melanoma risk	455	1.05 (0.79–1.40)	None	Age, gender, education, family history of melanoma, history of skin cancer, moles, freckles, sunburns, hair color, skin type, and total energy intake	Asgari et al, ⁵⁹ 2009
Cod liver oil intake	Norway	Melanoma risk	108	Women, 2.9 (1.7–5.1); men, 1.1 (0.5–2.6)	None	Age, height, BMI, BSA, education, smoking, and physical activity	Veierød et al, 1997
Randomized controlled trial	USA	Melanoma risk	176/36, 282	Overall, 0.86 (0.64–1.16); previous NMSC, 0.43 (0.21–0.90)	Yes, [†] for women with previous NMSC	Placebo—18,106 women; calcium and Vitamin D (1000 mg, 400 IU)—18,176	Tang et al, ⁶¹ 2011

BMI, Body mass index; BSA, body surface area; CI, confidence interval; IU, International Unit; NMSC, nonmelanoma skin cancer; OR, odds ratio; RR, relative risk.

* Data from Nurnberg et al⁵⁶ do not allow for calculation of odds ratio.

⁷ Study shows benefit of higher vitamin D serum levels or higher vitamin D intake.

NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Table II

Serum 25-hydroxyvitamin D (25[OH]D) concentrations and health*

ng/mL [†]	nmol/L	Health status
<12	<30	Associated with vitamin D deficiency and rickets in infants and young children
<12–20	<30–50	Generally considered inadequate for bone and overall health in healthy individuals
20	50	Generally considered adequate for bone and overall health in healthy individuals
30	75	Proposed by some as desirable for overall health and disease prevention, although a recent government-sponsored expert panel concluded that insufficient data are available to support these higher levels
>50	>125	Emerging evidence links potential adverse effects to high levels; can lead to hypercalcemia and hyperphosphatemia.

* Serum concentrations of 25(OH)D are reported in both nanograms per milliliter (ng/mL) and nanomoles per liter (nmol/L).

[†] 1 ng/mL = 2.5 nmol/L.

Table III

Current recommended upper limit levels of International Units of vitamin D that covers the needs of >97.5% of the US population*

Age	Children	Adults
0–6 mo	1000	—
6–12 mo	1500	—
1–3 yrs	2500	—
4–8 yrs	3000	—
9–50 yrs	4000	4000
51–70 yrs	—	4000
71 yrs	—	4000

*Data taken from Ross et al.⁶⁴